I will try to be quick then.
I appreciate that, and I understand the concerns that Canadian families have experienced over adverse drug reactions. Of course, you probably know one of our members of Parliament is here, elected for that very reason, and we work closely with him on this issue.
We introduced in our Speech from the Throne a commitment to moving forward with patient safety legislation. I can't get into the details of the legislation, but I want to reassure you that we are working closely with multiple stakeholders, including patient safety advocates, to ensure that we do get this right. We'll have a chance as well for that legislation to come before committee.
I have also recently asked Health Canada to begin to publish more transparently their drug reviews. I think that's important information that regular Canadians should have access to. Some of it is difficult to understand, but I don't think that should be a reason to not make it available to Canadians, and of course to researchers and physicians who would like to have that level of information. I hope to see a template from Health Canada soon on what that would look like, so we can ensure that we do publish that data more transparently when it comes to drug reviews. Of course, when it comes to adverse drug reactions, that's something we also hope to address in the patient safety legislation.